Table 2.
Promising Compounds in Clinical Development for the Treatment of Schizophrenia in Adults6
| Drug Developer | Description | Targeted Indication(s) | Expected Pricing Strategy | Anticipated U.S. Launch Date |
|---|---|---|---|---|
| Atypical Antipsychotics | ||||
| ALKS 3831 Alkermes | Fixed-dose combination of mu-opioid receptor antagonist (samidorphan) and atypical antipsychotic (olanzapine) | Schizophrenia (acute exacerbations or stable disease) | Priced at premium to olanzapine (Zyprexa, Lilly) | Third quarter of 2019 |
| AVN-211 Avineuro Pharmaceuticals | 5-HT6 receptor antagonist | Cognitive impairments associated with schizophrenia | Undetermined | Undetermined |
| ITI-007 Intra-Cellular Therapies | 5-HT2A receptor antagonist | Acute and residual schizophrenia | Priced at premium to currently marketed oral antipsychotics | First half of 2018 |
| Lu AF35700 Lundbeck | D1, 5-HT2A, and 5-HT6 receptor antagonist | Treatment-resistant schizophrenia | Undetermined | Undetermined |
| MIN-101 Minerva Neurosciences | 5-HT2A and sigma-2 receptor antagonist | Schizophrenia | Priced at premium to currently marketed oral antipsychotics | 2019 |
| RBP-7000 Indivior | Sustained-release risperidone | Schizophrenia (acute or maintenance treatment) | Priced at premium to Risperdal Consta (Janssen) | Fourth quarter of 2017 |
| Risperidone implant Braeburn Pharmaceuticals | Six-month, nonbiodegradable, drug-eluting stent | Schizophrenia (maintenance treatment) | Priced at 15% premium to annual cost of therapy with Risperdal Consta | Second quarter of 2018 |
| Risperidone ISM Rovi Pharmaceutical Laboratories | Once-monthly IM formulation based on ISM delivery system | Schizophrenia or schizoaffective disorder | Priced at premium to Risperdal Consta | Fourth quarter of 2019 |
| Hyperammonemia Agent | ||||
| Sodium benzoate (NaBen) SyneuRx International (Taiwan) Corp. | D-amino acid oxidase inhibitor |
|
Undetermined | Undetermined |
5-HT = 5-hydroxytryptamine; IM = intramuscular; ISM = in situ microparticles.